Dr Laila Abdel Wareth, CEO of the Diagnostic Cluster at M42, tells Sarah Cartledge about the science behind prevention
Abu Dhabi is moving healthcare beyond treating illness towards improving population health through earlier detection and co-ordinated prevention. Investment in genomics, digital infrastructure and advanced diagnostics is making it possible to identify risk sooner and intervene before disease becomes established.
At the centre of this work is Dr Laila Abdel Wareth, CEO of the Diagnostic Cluster at M42 and a clinical pathologist and medical biochemist. The cluster includes the National Reference Laboratory (NRL), Capital Health Screening Centre and Tolah Molecular Imaging Centre, bringing together capabilities that support prevention, diagnosis and treatment.
Diagnostic scale
NRL operates laboratories across M42’s healthcare assets, including Cleveland Clinic Abu Dhabi, and acts as a regional referral centre for complex testing. Its scale allows specialised expertise to be concentrated while routine processes remain efficient. “We receive all second opinion cases and all high complexity reference work where ordinary clinical labs do not have the expertise,” says Dr Laila.
More than 200 pathologists work across the network. Digital pathology allows cases to be reviewed remotely, enabling specialists to share expertise across locations and provide overnight reporting. The model is designed to combine quality with affordability, extending access to advanced diagnostics across the Gulf.
Alongside referral work, the network supports screening programmes and hospital care, giving its teams visibility across the patient pathway. This breadth matters because prevention depends on reliable testing at scale, followed by results that clinicians can interpret quickly and use confidently. For Dr Laila, diagnostics are therefore the foundation of earlier intervention.
Genomics and prediction
M42’s Omics Centre is separate from the Diagnostic Cluster but closely complementary. Through the Emirati Genome Programme, more than 900,000 Emiratis have been sequenced, creating an exceptional resource for understanding inherited risk within the population.
The Pharmacogenomics Project is translating that information into clinical care. Reports can be made available through Malaffi, Abu Dhabi’s health information exchange, helping clinicians understand how a patient’s genetic profile may influence their response to particular medicines.
Combining genomic information with clinical data could also allow health services to predict disease risk more accurately. “We have an amazing set of data, so now we need to train the machine to make predictions,” says Dr Laila. She expects proof-of-concept work to show how these insights can guide personalised prevention over the next few years:
Earlier Alzheimer’s detection
An early focus onAlzheimer’s disease and a collaboration with UK-based Re:Cognition Health, developed after discussions at Healthcare World events, is exploring the role of blood biomarkers in identifying risk before symptoms appear. As changes associated with Alzheimer’s may be detectable 10 to 15 years before clinical symptoms, earlier identification could give patients time to address factors that may influence cognitive health and consider appropriate treatment as it becomes available.
Sleep deprivation and metabolic health can also affect risk, making prevention a combination of genetic insight, clinical evidence and changes in daily life. If the work proves effective, the model could be extended across the UAE and the wider Gulf.
Earlier prediction brings difficult questions, requiring patient counselling to understand the meaning and limitations of a result, particularly when the risk may never develop into disease. Strong safeguards are also necessary to prevent genetic or predictive information being misused by insurers or employers
An early cancer blood test, for example, might reveal a potential condition before it can be confirmed clinically. Without clear regulation and legal protection, such information could affect insurance decisions while leaving the patient with uncertainty. “These are obviously moral hazards and ethical dilemmas here so the confidentiality of these records is paramount,” Dr Laila says.
Prevention first
Insurance systems traditionally pay once a person is ill, while preventive tests may sit outside standard coverage. Abu Dhabi’s population studies could thus help demonstrate the clinical and economic value of earlier intervention. Evidence from local pilots may then support discussions with payers about including proven screening tools in insurance packages.
Patients will also play a greater role. Dr Laila points to growing awareness of inherited breast cancer risk, with younger women increasingly seeking information and testing. As knowledge expands, public expectations will move faster than traditional funding models.
For Abu Dhabi, preventative healthcare is becoming a practical system built on diagnostic capacity, connected data and responsible use of genomic insight. Its success will depend on retaining public trust while ensuring that earlier knowledge leads to meaningful care. If those foundations are secured, prevention can move from ambition to everyday clinical practice.
Have some thoughts on the topic? Share them with the community here